drugset / Trial / NCT00621049
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Phase 2
Completed
112 enrolled
SCRI Development Innovations, LLC
Genentech, Inc. · collabSanofi · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Timeline
- Start
- 2007-12
- Primary completion
- 2013-07
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Comparator | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |